Pirinixil structure
|
Common Name | Pirinixil | ||
---|---|---|---|---|
CAS Number | 65089-17-0 | Molecular Weight | 366.86600 | |
Density | 1.37g/cm3 | Boiling Point | 609.6ºC at 760 mmHg | |
Molecular Formula | C16H19ClN4O2S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 322.5ºC |
Use of PirinixilPirinixil is a hypolipidemic agent of low toxicity. |
Name | 2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanyl-N-(2-hydroxyethyl)acetamide |
---|---|
Synonym | More Synonyms |
Description | Pirinixil is a hypolipidemic agent of low toxicity. |
---|---|
Related Catalog | |
In Vivo | Pirinixil is a hypolipidemic agent of low toxicity. Total cholesterol is reduced by Pirinixi in the spleen, kidney and heart of rats. Pirinixil decreases the estimated total body cholesterol approximately 40%[1]. Pirinixil increases plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides are markedly reduced by Pirinixil, while combined plasma and liver lipid levels decrease approximately 20%. Liver HMG-CoA reductase activity is not affected, but cholesterol 7α-hydroxylase is significantly reduced by Pirinixil[2]. |
Animal Admin | Male Sprague-Dawley rats, weighing 220 to 230 g at the start of each experiment, are used in all studies. They are kept in an air-conditioned environment, with controlled lighting and free access to water. Dietary treatments are (A) standard diet for rats and (B) 2% cholesterol+2% cholic acid regimen. Both diets are administered ad libitum, respectively for 1 and 2 weeks (standard diet) and for 2 weeks (cholesterolcholic acid diet). Groups of 5 rats in each of the 3 experiments (1 and 2 weeks with the standard diet, 2 weeks with the cholesterol-cholic acid diet) are administered Pirinixil daily in carboxymethylcellulose vehicle by gastric intubation, at the doses of 20 mg/kg. Controls are given a similar volume of vehicle daily by intubation[1]. |
References |
Density | 1.37g/cm3 |
---|---|
Boiling Point | 609.6ºC at 760 mmHg |
Molecular Formula | C16H19ClN4O2S |
Molecular Weight | 366.86600 |
Flash Point | 322.5ºC |
Exact Mass | 366.09200 |
PSA | 112.44000 |
LogP | 3.15490 |
Index of Refraction | 1.642 |
Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
~% Pirinixil CAS#:65089-17-0 |
Literature: L'Instituto Farmaceutico S.p.A. Patent: US4188484 A1, 1980 ; |
~% Pirinixil CAS#:65089-17-0 |
Literature: L'Instituto Farmaceutico S.p.A. Patent: US4188484 A1, 1980 ; |
~56% Pirinixil CAS#:65089-17-0 |
Literature: d'Atri; Gomarasca; Resnati; Tronconi; Scolastico; Sirtori Journal of Medicinal Chemistry, 1984 , vol. 27, # 12 p. 1621 - 1629 |
~% Pirinixil CAS#:65089-17-0 |
Literature: d'Atri; Gomarasca; Resnati; Tronconi; Scolastico; Sirtori Journal of Medicinal Chemistry, 1984 , vol. 27, # 12 p. 1621 - 1629 |
~% Pirinixil CAS#:65089-17-0 |
Literature: d'Atri; Gomarasca; Resnati; Tronconi; Scolastico; Sirtori Journal of Medicinal Chemistry, 1984 , vol. 27, # 12 p. 1621 - 1629 |
~% Pirinixil CAS#:65089-17-0 |
Literature: d'Atri; Gomarasca; Resnati; Tronconi; Scolastico; Sirtori Journal of Medicinal Chemistry, 1984 , vol. 27, # 12 p. 1621 - 1629 |
~% Pirinixil CAS#:65089-17-0 |
Literature: L'Instituto Farmaceutico S.p.A. Patent: US4188484 A1, 1980 ; |
2-[4-chloro-6-(2,3-dimethyl-anilino)-pyrimidin-2-ylsulfanyl]-N-(2-hydroxy-ethyl)-acetamide |
Pirinixil |
BR-931 |
<<4-chloro-6-<(2,3-dimethylphenyl)amino>-2-pyrimidinyl>thio>-N-(2-hydroxyethyl)acetamide |
2-((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)-N-(2-hydroxyethyl)acetamide |
Pirinixilo [Spanish] |
Pirinixilum [INN-Latin] |
Pirinixilo [INN-Spanish] |